SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial To Continue Without Any Modifications
Portfolio Pulse from Happy Mohamed
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC). The IDMC recommended that the trial continue without modifications. The interim analysis is expected to occur by late 2023 or early 2024, with enrollment completion anticipated in Q4 2023.
August 22, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive review of SELLAS Life Sciences' ongoing Phase 3 REGAL clinical trial by the IDMC is a positive signal for the company. The trial's continuation without modifications indicates that the trial is progressing as expected, which could boost investor confidence in the short term.
The positive review by the IDMC indicates that the trial is progressing as expected, which is a positive signal for the company. This could boost investor confidence in the short term, potentially leading to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100